{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:08:27Z","timestamp":1793254107297,"version":"4.5.0"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To re\u2010evaluate the safety of hormonal contraceptives (HC) after uterine evacuation of complete hydatidiform mole (CHM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Historical database review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Charing Cross Hospital Gestational Trophoblastic Disease Centre, London, United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Population<\/jats:title>\n                    <jats:p>Two thousand four hundred and twenty\u2010three women with CHM of whom 154 commenced HC while their human chorionic gonadotropin (hCG) was still elevated, followed between 2003 and 2012.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared time to hCG remission between HC users and nonusers. The relationship between HC use and gestational trophoblastic neoplasia (GTN) development was assessed. The relationship between HC use and a high International Federation of Gynecology and Obstetrics (FIGO) risk score was determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Time to hCG remission, risk of developing postmolar GTN and proportion of women with high FIGO risk score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No relationship was observed between HC use with mean time to hCG remission (HC users versus non\u2010users: 12\u00a0weeks in both,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.19), GTN development (HC users versus non\u2010users: 20.1 and 16.7%,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.26) or high\u2010risk FIGO score (HC users versus nonusers: 0% and 8%,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.15). Moreover, no association between HC and GTN development was found, even when an age\u2010adjusted model was used (OR = 1.37, 95% CI 0.91\u20132.08,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.13).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of current HC is not associated with development of postmolar GTN or delayed time to hCG remission. Therefore, HC can be safely used to prevent a new conception following CHM regardless of hCG level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Tweetable abstract<\/jats:title>\n                    <jats:p>Non\u2010concurrent cohort study to re\u2010evaluate the safety of low dose HCs after uterine evacuation of CHM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1471-0528.13617","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T10:51:44Z","timestamp":1444215104000},"page":"1330-1335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hormonal contraceptive use before\n                    <scp>hCG<\/scp>\n                    remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review"],"prefix":"10.1111","volume":"123","author":[{"given":"A","family":"Braga","sequence":"first","affiliation":[{"name":"Trophoblastic Disease Center Maternity School of Rio de Janeiro Federal University and Antonio Pedro University Hospital at Fluminense Federal University Rio de Janeiro Brazil"},{"name":"Postdoctoral Program of Science without Borders (Brazilian Government) \u2013 Charing Cross Gestational Trophoblastic Disease Centre Charing Cross Hospital Imperial College School of Medicine London UK"},{"name":"Postdoctoral Program of Gynecology Obstetrics and Mastology Postgraduate of Botucatu Medical School UNESP\u2010 S\u00e3o Paulo State University Botucatu S\u00e3o Paulo Brazil"},{"name":"Trophoblastic Disease Center Department of Gynecology and Obstetrics Botucatu Medical School UNESP \u2013 S\u00e3o Paulo State University Botucatu S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Maest\u00e1","sequence":"additional","affiliation":[{"name":"Trophoblastic Disease Center Department of Gynecology and Obstetrics Botucatu Medical School UNESP \u2013 S\u00e3o Paulo State University Botucatu S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Short","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Disease Centre Charing Cross Hospital Imperial College School of Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Savage","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Disease Centre Charing Cross Hospital Imperial College School of Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Harvey","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Disease Centre Charing Cross Hospital Imperial College School of Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MJ","family":"Seckl","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Disease Centre Charing Cross Hospital Imperial College School of Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60280-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.06.073"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.07.116"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(12)60026-5"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt345"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.09.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.462"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0900696"},{"key":"e_1_2_6_10_1","volume-title":"Medical eligibility criteria for contraceptive use","author":"World Health Organization"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1976.tb00774.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1979.tb10694.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92510-6"},{"key":"e_1_2_6_14_1","first-page":"474","article-title":"Oral contraceptives and postmolar trophoblastic disease","volume":"58","author":"Berkowitz RS","year":"1981","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_15_1","first-page":"736","article-title":"Postmolar trophoblastic disease in women using hormonal contraception with and without estrogen","volume":"62","author":"Eddy GL","year":"1983","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(85)90669-6"},{"key":"e_1_2_6_17_1","first-page":"221","article-title":"The role of contraception in the development of postmolar trophoblastic tumor","volume":"78","author":"Deicas RE","year":"1991","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_18_1","first-page":"590","volume-title":"Kongres Obstetri Ginekologie Indonesia","author":"Utoro AS","year":"1992"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1987.tb02246.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(83)90494-5"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(89)90295-0"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/01443610063516"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.09.031"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.03.022"},{"key":"e_1_2_6_25_1","first-page":"285","article-title":"Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors","volume":"55","author":"Harvey RA","year":"2010","journal-title":"J Reprod Med"},{"key":"e_1_2_6_26_1","unstructured":"Royal College of Obstetricians and Gynaecologists.The management of gestational trophoblastic disease. Green\u2010Top Guideline n.38. 2010. Available in [http:\/\/www.rcog.org.uk\/files\/rcog-corp\/GT38ManagementGestational0210.pdf] (accessed 1 June 2015)."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61265-8"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10024-002-0079-9"},{"key":"e_1_2_6_29_1","unstructured":"Faculty of Sexual & Reproductive Healthcare Care. UK Medical Eligibility Criteria for Contraceptive Use. 2009. Avaliable at: [http:\/\/www.fsrh.org\/admin\/uploads\/UKMEC2009.pdf] (accessed 1 June 2015)."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625180410001715681"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200012000-00014"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.297"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(81)90197-5"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1995.tb01524.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.110.083535"},{"key":"e_1_2_6_36_1","first-page":"891","article-title":"Genistein inhibits placental\u00a0choriocarcinoma\u00a0cell line JAR invasion through ER\u03b2\/MTA3\/Snail\/E\u2010cadherin pathway","volume":"2","author":"Liu X","year":"2011","journal-title":"Oncol Lett"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.09.010"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1471-0528.13617","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1471-0528.13617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:10:00Z","timestamp":1696288200000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/1471-0528.13617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/1471-0528.13617"],"URL":"https:\/\/doi.org\/10.1111\/1471-0528.13617","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]},"assertion":[{"value":"2015-07-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}